Seeking a Clinical Trial in Vitiligo

Seeking a Clinical Trial in Vitiligo

Clinical trials help researchers learn whether new ways to diagnose, manage, or treat vitiligo are safe and effective.

They may test a medicine, light therapy, procedure, or combination of treatments. Some studies simply follow people over time to help us better understand vitiligo — no experimental treatment involved.

If clinical trials feel like unfamiliar territory, visit our FAQ section for clear answers to common questions and concerns.

Use the search below to explore active vitiligo studies and find recruitment sites near you.

Find a Vitiligo Trial That May Fit You

By leaving your email you agree to our Privacy Policy.

Vitiligo Studies Recruiting Now

66 trials in total

  • 01 Apr `25
    This clinical study aims to compare the safety and effectiveness of two treatments-oral Tacrolimus capsules and Dexamethasone micro-pulse therapy-in children aged 4-12 years with rapidly progressing vitiligo. The study is a multicenter, randomized...

    Location: Xijing Hospital, Xi'an, Shaanxi, 710032, China
  • 25 Mar `25
    Forte Biosciences, Inc. plans to enroll about 64 participants. FB102 is an experimental antibody that targets CD122 and changes IL-2 and IL-15 immune signaling. It is intended to reduce disease-driving T-cell activity so melanocytes can recover an...

    Location: 6 listed sites: Australia (3); New Zealand (3)
  • 01 Mar `25
    This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.Phase: Phase 4.What is be...

    Location: Khyber Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan
  • 01 Feb `25
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS plans to enroll about 400 participants. This is an observational study, so researchers will not assign an experimental treatment. Researchers are studying public attitudes and stigma towa...

    Location: Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia, Roma, Italia, Italy (Recruiting)
  • 04 Dec `24
    Jilin University plans to enroll about 60 participants. Upadacitinib is an oral JAK inhibitor that reduces inflammatory immune signaling. Researchers hope it will slow melanocyte destruction and improve repigmentation, alone or after cell transpla...

    Location: Department of Dermatology and Venerology, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin, China (Recruiting)
  • 29 Nov `24
    This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient prev...

    Location: Queen Mary Hospital, Hospital Authority, Hong Kong, Hong Kong
  • 02 Oct `24
    vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple...

    Location: Qena university hospital, Qena faculty of medicine, Qina, Egypt
  • 25 Apr `24
    To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and provi...

    Location: Peking University People's Hospital, Beijing, Beijing Municipality, 100044, China
  • 15 Oct `22
    Al-Azhar University plans to enroll about 60 participants. Fluorouracil is applied after needling or laser treatment to encourage pigment cells to move into pale skin. Researchers hope the combination will improve repigmentation in stable vitiligo...

    Location: Facualty of Pharmacy, Al Azhar University, Cairo, Egypt (Recruiting)
  • 30 May `21
    Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer...

    Location: Northwestern University, Chicago, Illinois, 60611, United States
  • 01 Sep `26
    Vitiligo affects approximately 1 to 2% of the global population and significantly impacts people's quality of life. Achieving the best treatment outcomes for vitiligo involves addressing the autoimmune inflammatory response for stopping the depigm...

    Location: CHU de Nice, Nice, Alpes-maritimes, 06200, France
  • 01 Aug `26
    TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual c...

    Location: Greenwich Village Dermatology, New York, New York, 10012, United States
  • 01 Jul `26
    This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo l...
  • 01 Jun `26
    This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar...

    Location: MTI-HMC Peshawar, Peshawar, Khyber Pukhtunkhwa, 25000, Pakistan
  • 01 Jun `26
    The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo. The main question this clinical trial aims to answer is: • Can ACT-777991 help return colo...

    Location: No study locations reported
  • 01 Jun `26
    This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in tr...

    Location: No study locations reported
  • 01 Jun `26
    The Children's Hospital of Zhejiang University School of Medicine plans to enroll about 20 participants. Ruxolitinib cream blocks JAK1 and JAK2 signals that help sustain the immune attack on pigment-producing cells. It is intended to calm inflamma...

    Location: Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
  • 31 May `26
    This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo. Drawing on the prior/preclinical da...

    Location: No study locations reported
  • 20 May `26
    This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo. It aims to evaluate both clinical and histopathological outcome...

    Location: No study locations reported
  • 15 May `26
    Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo ofte...

    Location: The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, United Kingdom
  • 01 May `26
    Assiut University plans to enroll about 50 participants. The procedure makes controlled tiny injuries in the skin, sometimes to improve delivery of a medicine or add targeted UVB light. This may stimulate healing and help pigment cells move into o...

    Location: No study locations reported
  • 01 Apr `26
    This study evaluates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUMSCs-Exo) are safe and effective for treating vitiligo in adults. Vitiligo is a skin condition that causes white patches due to loss of pigment-produ...

    Location: Xijing Hospital, The First Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, 710032, China
  • 18 Mar `26
    Yohanes Firmansyah, dr, MH, MM plans to enroll about 150 participants. This experimental treatment uses cell-derived particles and signaling proteins intended to change inflammation and tissue repair. Researchers hope these signals will protect me...

    Location: Klinik Precious Me, Tangerang, Banten, Indonesia
  • 15 Mar `26
    The goal of this clinical trial is to learn if adding mini-oral pulse steroid therapy improves the results of non-cultured epidermal cell suspension (NCES) surgery in patients with stable vitiligo. It will also evaluate the safety of this treatmen...

    Location: Dermatology out patient clinic, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt
  • 20 Jan `26
    Xijing Hospital plans to enroll about 60 participants. The study removes halo moles, which are surrounded by pale skin, to see whether they help drive immune activity in vitiligo. Researchers want to learn whether removal can help stabilize diseas...

    Location: Xijing Hospital, Xi'an, Shaanxi, China
Clinical Trials Alerts

Sign up and be the first to know when new trials are starting nearby.


FAQOther Questions

  • What is the best therapy for localized vitiligo?

    Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...

  • Is it possible to stop the progression of vitiligo?

    While it's not always possible to quickly stop vitiligo progression, there are some treatments that can help slow or halt the spread of the condition in many cases: Corticostero...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...